

## Redefining the approach to advanced prostate cancer

Industry session by JANSSEN PHARMACEUTICA NV

**Saturday, 25 March**  
**18:00 - 19:30**

**Location:** Room Milan, North Hall (Level 1)

**Chairs:** K. Fizazi, Villejuif (FR)  
K. Miller, Berlin (DE)

### **Aims and objectives of this session**

At the end of this symposium delegates should be able to:

- Explain the importance of different mHSPC presentations and tumour load, and how this may influence management
- Analyse the evidence for selecting a certain treatment from the current treatment options for mCRPC
- Explain the importance of comorbidities, drug interactions, and other patient characteristics, and how these can affect treatment decisions for patients with metastatic prostate cancer
- Describe the importance of investigating and developing biomarkers that might drive therapeutic decisions for patients with prostate cancer in the future

18:00 - 18:05

### **Welcome and introduction**

K. Miller, Berlin (DE)

18:05 - 18:25

### **Should all patients get docetaxel for metastatic hormone-sensitive prostate cancer?**

K. Fizazi, Villejuif (FR)

18:25 - 18:45

### **Should all patients get androgen-targeted therapy for first-line in metastatic castration-resistant prostate cancer?**

K. Miller, Berlin (DE)

18:45 - 19:05

### **Panel discussion - Treating the patient with metastatic disease: Clinical case discussions**

C.P. Evans, Sacramento (US)

K. Fizazi, Villejuif (FR)

K. Miller, Berlin (DE)

19:05 - 19:25

### **CRPC Variants and clinical implications**

C.P. Evans, Sacramento (US)

19:25 - 19:30

### **Close of meeting**

K. Fizazi, Villejuif (FR)